Main Article Content
Lymphoma is a heterogeneous group of malignancies derived from the lymphoid system that accounts for roughly 4 % of cancers worldwide. A significant improvement during the last decade was made possible with the introduction of an anti-CD20 monoclonal antibody, rituximab, which has been utilized widely in the treatment of B cell lymphomas leading to significantly better outcomes, which in part have contributed to the reduced mortality rates. Various factors like lifestyle, genetics, environment, age, ethnicity and gender are risk factors of lymphoma. Other factors include Socioeconomics, marital status, educational background, history of drinking or smoking and obesity. Globally, lymphoma is the sixth most common malignancy. HL is second most common lymphoma in developed countries whereas third most common malignancy in developing countries. NHL is eleventh most occurring cancer in males and eighth most common in female. Lymphoma is more common in men. In Pakistan HL accounts for 4.9% and NHL is approximately 4.7%. Prevalence of lymphoma cancer in Balochistan is about 9.6%.
Keywords: Angiogenic; Biological markers; Epidemiology; Hodgkin lymphoma; Lymphoma; Non-Hodgkin lymphoma